

AUTHOR INDEX

Volume 42

July to December 1990

- Acosta, M., 159
 Ahmed, S., 297
 Ahmed, Y.H., 297
 Akhter, H.H., 297
 Alapiessa, U., 285
 Alvarado, G., 159
 Alvarez, F., 361, 379
 Angel de Toro, L.A., 13
 Apter, D., 285, 629
 Assendorp, R., 201, 285
 Bajpai, V.K., 655
 Bakos, O., 51
 Bandaragoda, J., 159
 Barbosa, I., 51
 Bardhan, J., 479
 Belhadj, H., 97
 Betancourt, J.D., 159
 Bhartiya, D., 655
 Bhatia, G.S., 337
 Birgersson, L., 275
 Bitsch, M., 315
 Bouckaert, P., 201
 Bounds, W., 263
 Brache, V., 361, 379
 Burren, T., 263
 Bygdeman, M., 323
 Cacciatore, B., 285
 Chen, A-J, 455
 Chen, J-k, 439
 Chi, I-c, 159
 Chowdhury, J.B., 297
 Colling-Saltin, A-S, 275
 Coutinho, E., 361
 Croxatto, H.B., 97
 Danforth, D.R., 209
 Darwish, E., 29
 Davignon, J., 225
 Desrosiers, J.A.J., 253
 Devakumar, C., 479
 Dhar, J.D., 121, 655
 Diao, X-H, 687
 Diaz, J., 361, 379
 Diaz, M.M., 361
 Diaz, R.S., 13
 Díaz, S., 97, 361, 379
 Dieben, T., 201
 Edelstein, M.C., 209
 El Mahgoub, S., 361
 El Sokkary, H., 29
 Faisel, A.J., 297
 Falsetti, L., 611
 Fan, S-b, 439
 Farquhar, D., 225
 Farr, G., 159
 Faundes, A., 361
 Fotherby, K., 439, 455
 Frølund, C., 315
 Fugère, P., 225
 Galbignani, E., 611
 Gemzell, K., 323
 Gordon, K., 209
 Gua, M.W., 391
 Gui, Y-l, 439
 Guilbert, E., 253
 Guillebaud, J., 263
 Haller, H., 35
 Haukkamaa, M., 111
 He, M-l, 439
 Heikinheimo, O., 111
 Hiremath, S.P., 467
 Hodgen, G.D., 209
 Ilavazhagan, G., 479
 Indian Council of Medical
 Research Task Force on
 Hormonal Contraception, 179
 Jacobsen, B.K., 171
 Jakobsen, A.B., 315
 Jiang, H-Y, 455
 Jimenez, E., 361
 Johannisson, E., 403
 Johansen, R.L., 693
 Johansson, E., 1, 51
 Jung-Hoffmann, C., 423
 Kain, A.K., 479
 Kaminski, J., 687
 Kapu, M.M., 621
 Kaur, J., 349
 Khamis, Y., 29
 Klomp, A., 309
 Kuhl, H., 423
 Krutli, D.R., 309
 Laurikka-Routti, M., 111
 Lavarello, A.C.M., 13
 Kewubm LM., 677
 Li, J.Z., 391
 Li, L-n, 439
 Lu, F-Y, 455
 Lund, E., 171
 Lussier-Cacan, S., 225
 Machin, S.J., 263
 Mackie, I.J., 263
 MacLennan, A.H., 309
 Mateo, J.M.R., 13

CONTRACEPTION

- Mattos, C.E.R., 361
 McCarthy, T., 361
 Medhat, I., 643
 Meng, Y-X, 455
 Mishell, D.R., Jr., 361
 Misra, H.P., 693
 Moby El Dien, Y., 643
 Nabrink, M., 275
 Odland, V., 1, 51, 379
 Ollo, M.A., 29, 643
 Olsson, S-E., 1, 51, 379
 Pavez, M., 97, 361, 379
 Percival-Smith, R.K.L., 225, 253
 Pholpramool, C., 677
 Pienaar, C.A., 597
 Prien-Larsen, J.C., 315
 Qian, L.J., 391
 Quigg, J., 687
 Rajalakshmi, M., 235, 349
 Ramakrishnan, P.R., 235, 349
 Randic, L., 35
 Rao, S.H., 467
 Riari, S.S., 479
 Rioux, J.E., 253
 Rivera, R., 159
 Rizh, M., 643
 Robinson, G.E., 263
 Rodrigues, L.V., 309
 Roumen, F., 201
 Roy, S., 67
 Ruchirawat, S., 677
 Rukavina, D., 35
 Sagasta, C.L., 13
 Schall, R., 597
 Sederberg-Olsen, J., 315
 Sethi, N., 215, 337
 Setty, B.S., 121
 Shaaban, M., 379
 Shaban, N., 643
 Shao, Q-X, 455
 Shen, K-Y, 455
 Shoupe, D., 361
 Singh, B., 479
 Singh, R., 479
 Singh, R.K., 215, 337
 Sinha, N., 337
 Sivin, I., 97, 361, 379
 Sohnus, U., 597
 Solum, T., 275
 Song, S., 439
 Souka, A.R., 29
 Srivastava, R.K., 215, 337
 Stanczyk, F.Z., 67
 Stenman, U-H, 285
 Stern, J., 97, 361
 Stocks, J., 263
 Sun, D-L, 455
 Sung, L.J., 391
 Susa, M., 35
 Swahn, M.L., 323
 Thomas, P., 479
 Thompson, K., 159
 Timmer, C.J., 629
 Urquhart, D.R., 191
 Van Der Spuy, Z.M., 597
 Verawatnapakul, V., 677
 Voortman, G., 629
 Wada, I., 621
 Wang, M.Y., 391
 Wiemeyer, J.C.M., 13
 Williams, R.F., 209
 World Health Organization
 Task Force on the Safety
 and Efficacy of Fertility
 Regulating Methods, 141
 Wright, E.A., 621
 Yang, H., 455
 Yang, P-J, 439
 Yuzpe, A.A., 253
 Zaneveld, L.J.D., 687
 Zhang, M-Y, 455
 Zou, S-l, 687

SUBJECT INDEX

Volume 42

July-December, 1990

- Acaceticin from *S. lutea* plant, antifertility efficacy (rat), 467
- Acne treatment, use of ethinyl estradiol + cyproterone acetate, 225, 611
- 3 Ad (testosterone-cis-3-(n-hexyl) cyclobutane carboxylate), effect on serum levels of testosterone (monkey), 235
- 20 Aet-2 (testosterone-trans-4-n-pentyl cyclohexyl carboxylate), effect on serum levels of testosterone (monkey), 235
- Alcohol consumption, relationship to oral contraceptive use, 171
- Alkyloxynol-741 (alkylphenoxy ethanol), effect as vaginal spermicide (monkey), 677
- Ampicillin, use following minilaparotomy sterilization, 297
- Anandron (RU 23908; 5,5-dimethyl-3(4-nitro-3,3-trifluoromethyl)phenyl)-2,4-imidazolidinedione), effect on reproductive system and fertility (male rat), 121
- Androgen levels,
 effect of ethinyl estradiol + cyproterone acetate, 225
 effect of ethinylestradiol + desogestrel, 285
 effect of ethinylestradiol + 3-keto-desogestrel, 285
- Aniline hydroxylase activity, effect of gossypol (rat), 683
- Anticoagulant parameters, effect of estradiol valerate + norethisterone enantate, 455
- Antide (Nal-Lys GnRH antagonist), effect on testosterone secretion (monkey), 209
- Antiestrogenic activity, acaceticin and luteolin (rat), 467
- Antifertility efficacy, *Striga lutea* plant (rat), 467
- Bioavailability,
 ethinylestradiol and 3-keto-desogestrel from oral tablet, 629
 ethinylestradiol and 3-keto-desogestrel from vaginal rings, 629
- Biochemical parameters, comparison of effects of oral contraceptive pills, injectables and non-hormonal methods, 13
- Biochemical studies, effect of styrene maleic anhydride (monkey), 337
- Biphasic ethinylestradiol + norethindrone, effect on bleeding pattern, 253
- Bleeding, assessment of treatments in users of Norplant^R, 97
- Bleeding intensity, during use of ethinylestradiol + desogestrel, 275
- Bleeding pattern,
 use of 3-keto desogestrel implant, 1
 use of levonorgestrel-releasing IUD, 51
 use of low-dose oral contraceptives, 253

CONTRACEPTION

- use of norethisterone oenanthate, 179
- use of Nova-T, 51
- use of oestradiol valerate + norethisterone oenanthate, 179
- use of progestogen-only pills, 489
- use of vaginal ring releasing ethinylestradiol + 3-keto desogestrel, 563
- use of vaginal ring releasing ethinyl estradiol + ST-1435, 111
- Body weight, effect of styrene maleic anhydride (monkey), 337
- Breast milk ST-1435 level, following use of ST-1435 subcutaneous capsule, 555
- Caeruloplasmin level, effect of ethinyloestradiol + norethisterone, 439
- Carbohydrate metabolism, effect of ethinyloestradiol + norethisterone, 439
- Cells adherent to copper-bearing IUDs, studied with monoclonal antibodies, 35
- Cervical dilatation, effect of gemeprost vaginal pessaries, 43
- Cervical mucus,
 - use of levonorgestrel-releasing IUD, 51
 - use of Nova-T, 51
- Cervical priming, use of RU 486, 191
- Cervix, effect of local release of progestogens, 403
- Chemical composition of deposits formed on IUCDs, 643
- Chlorhexidine, effect of vaginal spermicide (monkey), 677
- Chronic toxicity study, styrene maleic anhydride (monkey, 337
- Clinical effects, vaginal ring releasing ethinylestradiol + 3-keto desogestrel, 563
- Clinical performance, vaginal ring releasing ethinyl-estradiol + 3-keto-desogestrel, 285
- Clip laparoscopic tubal ligation, effect of indomethacin on postoperative discomfort, 309
- Coagulation factors,
 - effect of estradiol valerate + norethisterone enantate, 455
 - effect of ethinyl oestradiol + desogestrel, 263
 - effect of ethinyl oestradiol + gestodene, 263
 - effect of ethinyloestradiol + norethisterone, 439
- Condom users, characteristics, 523
- Condoms,
 - effectiveness, acceptability and protective aspects, 621
 - influence on sexual performance, 621
 - side effects with use, 621
 - use and associated problems, 523
 - use as both contraceptive and disease preventive measures, 621
- Continuation rate, Mahua Ring, 391
- Contraception survey: Denmark 1988, 507

- Contraceptive use, influence of demographic and socio-economic factors, 507
- Copper IUCDs, study of surface deposits, 643
- Copper-bearing IUDs, study of adherent cells, 35
- Copper-releasing IUDs, clinical trial, 379
- Cycle control,
 - use of ethinyl estradiol + cyproterone acetate, 225
 - use of low-dose oral contraceptives, 253
- Cyproterone acetate, effect on spermatozoa maturation (monkey), 349
- Cytochrome P-450 and b_5 levels, effect of gossypol (rat), 683
- Demographic factors, influence on contraceptive use, 507
- Deposits formed on surface, study of copper and inert IUCDs, 643
- Desogestrel, metabolism, 67
- Dietary habits, relationship to oral contraceptive use, 171
- Discontinuation rate,
 - copper-bearing IUDs, 141
 - norethisterone oenanthate, 179
 - oestradiol valerate + norethisterone oenanthate, 179
- Discontinuations, use of progestogen-only pills, 489
- Disease preventive measures, use of condoms, 621
- Dysmenorrhea,
 - effect of ethinylestradiol + desogestrel, 275
 - influence of different combined oral contraceptives on prevalence and severity, 497
- Endocervix, effect of local administration of steroidal contraceptives, 403
- Endocrine parameters, effect of ethinylestradiol + cyproterone acetate, 611
- Endometrium, effect of local release of progestogens, 403
- Epididymis,
 - effect of Anandron (rat), 121
 - effect of vasectomy on in situ pH (rat), 589
- Estradiol enanthate + dihydroxyprogesterone acetophenide, metabolic effect, 13
- Estradiol level,
 - during week of placebo therapy in oral contraceptive pill users, 597
 - effect of ethinylestradiol + 3-keto-desogestrel, 285, 563
 - effect of ethinyl estradiol + ST-1435, 111
 - effect of ethynyloestradiol + norethisterone, 439
 - effect of 3-keto desogestrel, 1
 - effect of levonorgestrel, 51
 - effect of Nova-T, 51
 - effect of RU 486, 323
 - effect of tamoxifen, 323
- Estradiol valerate + norethisterone enanthate, effect on haematological parameters, 455
- Estrogenic activity, acacetin and luteolin (rat), 467
- Estrone-3-glucuronide level, effect of ethinyl estradiol + L-norgestrel, 29

CONTRACEPTION

- Ethinylestradiol, use in treatment for prolonged bleeding, 97
- Ethinyl estradiol + cyproterone acetate,
 - effect in patients with polycystic ovary syndrome, 611
 - use in treatment of acne, 225
- Ethinylestradiol + desogestrel,
 - clinical performance and endocrine profile, 285
 - effect on dysmenorrhoea, 275
 - effect on lipoprotein and coagulant protein levels, 263
 - intermenstrual bleeding, 423
 - serum contraceptive steroid levels, 423
- Ethinylestradiol + gestodene,
 - effect on lipoprotein and coagulant protein levels, 263
 - intermenstrual bleeding, 423
 - serum contraceptive steroid levels, 423
- Ethinylestradiol + 3-keto desogestrel vaginal ring,
 - acceptability and effect on ovulation, 563
 - clinical performance and endocrine profile, 285
- Ethinylestradiol + levonorgestrel,
 - effect on dysmenorrhea, 497
 - effect on lipid and lipoprotein metabolism, 535
 - metabolic effect, 13
- Ethinyl estradiol + lynestrenol, effect on dysmenorrhea, 497
- Ethinylestradiol + norethindrone acetate, effect on bleeding pattern, 253
- Ethinyl estradiol + L-norgestrel, effect on ovarian function, 29
- Ethinyl estradiol + ST-1435 vaginal ring, metabolic effects, effects on ovarian function, bleeding pattern, 111
- Ethinylestradiol level,
 - following use of ethinylestradiol + desogestrel, 423, 629
 - following use of ethinylestradiol + gestodene, 423
 - following use of ethinylestradiol + 3-keto desogestrel vaginal ring, 563, 629
 - following use of ethinyl estradiol + ST-1435 vaginal ring, 111
- Ethynodiol diacetate, metabolism, 67
- Ethynodiol diacetate POP, clinical experience, 489
- Ethynyloestradiol + norethisterone, pharmacodynamic and pharmacokinetic study, 439
- Ethynyloestradiol level, following use of ethynyloestradiol + norethisterone, 439
- Exocervix, effect of local administration of steroidal contraceptives, 403
- Expulsion, Nova-T insertion immediately following induced abortion, 315
- Expulsion rate,
 - copper-bearing IUDs, 159
 - copper-releasing IUDs, 379
 - levonorgestrel-releasing IUD, 361
 - Lippes Loop D, 159
 - Mahua Ring, 391
 - TCu 380Ag, 361

- Falope ring laparoscopic tubal ligation, effect of
indomethacin on postoperative discomfort, 309
- Fertility,
 - after reversal of styrene maleic anhydride occlusion
of vas (rabbit), 215
 - effect of Anandrone (male rat), 121
 - effect of sulphonamides (male rat), 667
 - women's knowledge assessed, 507
- First cycle urinary hormonal profile, use of ethinyl
estradiol + L-norgestrel, 29
- Flutamide, effect on reproductive system (male rat), 121
- Folate metabolism, effect of antifertility sulphonamides
(rat), 667
- Follicular development,
 - effect of levonorgestrel, 51
 - effect of Nova-T, 51
- FSH level, during week of placebo therapy in oral contra-
ceptive users, 597
- Gemeprost (16,16-dimethyl-trans- Δ^2 -prostaglandin E1 methyl
ester)
- Gemeprost vaginal pessaries, use in late second trimester
abortion, 43
- Gestodene, metabolism, 67
- Gestodene level, following use of ethinylestradiol +
gestodene, 423
- Glucose uptake by sperm, effect of gossypol, 573
- GnRH (gonadotropin releasing hormone)
- GnRH antagonist, Antide, 209
- Gossypol,
 - effect of spermatozoal glucose uptake, 573
 - effect on hepatic drug-metabolizing system (rat)
683
 - effect on spermatozoal lipid peroxidation, 573
- Gyne T 380, clinical trial, 379
- Gyne T 380 Slimline, clinical trial, 379
- Haematological parameters, effect of estradiol valerate +
norethisterone enantate, 455
- Haematological studies, effect of styrene maleic
anhydride (monkey), 337
- Haemoglobin concentration, effect of estradiol valerate +
norethisterone enantate, 455
- Hepatic drug-metabolizing system, effects of gossypol
(rat) 683
- Hirsutism, effect of ethinylestradiol + cyproterone
acetate, 611
- Hypothalamic-pituitary-ovarian axis, change during placebo
therapy week in oral contraceptive pill users, 597
- Ibuprofen, use in treatment for prolonged bleeding, 97
- Implant contraceptive,
 - 3-keto desogestrel, 1
 - levonorgestrel, 97
 - ST-1435, 555
- Indomethacin, effect on postoperative discomfort following
laparoscopic tubal ligation, 309

CONTRACEPTION

- Induced abortion, Nova-T insertion immediately following, 315
- Infection, following minilaparotomy sterilization, 297
- Injectable contraceptive,
 - estradiol enanthate + dihydroxyprogesterone acetophenide, 13
 - estradiol valerate + norethisterone enanthate, 455
 - norethisterone enanthate, 13, 179
 - oestradiol valerate + norethisterone oenanthate, 179
- Insertion issues, copper-releasing IUDs, 379
- Intermenstrual bleeding,
 - use of ethinylestradiol + desogestrel, 423
 - use of ethinylestradiol + gestodene, 423
- Intrauterine device (IUD),
 - copper, 643
 - Gyne T 380, 379
 - Gyne T 380 Slimline, 379
 - levonorgestrel-releasing, 51
 - Lippes Loop D, 159, 643
 - Mahua Ring, 391
 - Multiload 250, 141
 - Multiload Cu 250, 159
 - Nova-T, 51, 141, 315
 - releasing levonorgestrel, 361
 - TCu 200, 159
 - TCu 220, 159
 - TCu220C, 141
 - TCu380A, 141, 159
 - TCu 380Ag, 361
- Intrauterine release of progestogens, effect on endometrium, 403
- IUCD, IUD (intrauterine device)
- IUD-adherent cells, copper-bearing IUDs, 35
- IUDs,
 - summary of multicentre studies, 141
 - views of alleged advantages and disadvantages, 507
- 3-Keto desogestrel implant, clinical study, 1
- 3-Keto desogestrel level,
 - following use of ethinylestradiol + desogestrel, 423, 629
 - following use of ethinylestradiol + 3-keto desogestrel vaginal ring, 563, 629
 - following use of implant containing 3-keto desogestrel, 1
- Levonorgestrel,
 - metabolism, 67
 - use in treatment for prolonged bleeding in users of Norplant^R, 97
- Levonorgestrel implants, treatments for prolonged bleeding in users, 97
- Levonorgestrel level, following use of levonorgestrel-releasing IUD, 51
- Levonorgestrel POP, clinical experience, 489

- Levonorgestrel-releasing IUD,
 - clinical trial, 361
 - effect on ovarian function, 51
- LH (luteinizing hormone)
- LH level,
 - during week of placebo therapy in oral contraceptive pill users, 597
 - effect of ethinyl estradiol + L-norgestrel, 29
 - effect of levonorgestrel, 51
 - effect of Nova-T, 51
 - effect of RU 486, 323
 - effect of tamoxifen, 323
- Lipid and lipoprotein levels,
 - effect of ethinyl oestradiol + desogestrel, 263
 - effect of ethinyl oestradiol + gestodene, 263
- Lipid and lipoprotein metabolism, effect of ethinyl-estradiol + levonorgestrel, 535
- Lipid and lipoprotein profile, use of ethinyl estradiol + cyproterone acetate, 225
- Lipid levels, effect of ethinyl estradiol + ST-1435, 111
- Lipid metabolism, effect of ethinyloestradiol + norethisterone, 439
- Lipid peroxidation in sperm, effect of gossypol, 573
- Lippes loop, study of surface deposits, 643
- Lippes Loop D, removal due to bleeding and/or pain, 159
- Liver, effect of gossypol (rat), 683
- Luteolin from *S. lutea* plant, antifertility efficacy (rat), 467
- Lynestrenol, metabolism, 67
- Mahua Ring, contraceptive study of different sizes, 391
- Menstrual problems,
 - use of levonorgestrel-releasing IUDs, 361
 - use of TCu 380Ag, 361
- Mestranol + norethisterone, effect on dysmenorrhea, 497
- Metabolic effect,
 - estradiol enanthate + dihydroxyprogesterone acetophenide, 13
 - ethinylestradiol + cyproterone acetate, 611
 - ethinylestradiol + levonorgestrel, 13
 - norethisterone enanthate, 13
- Metabolism,
 - levonorgestrel, 67
 - norethindrone, 67
 - progestogens structurally related to levonorgestrel, 67
 - progestogens structurally related to norethindrone, 67
- Minilaparotomy sterilization, use of tetracycline or ampicillin following procedure, 297
- Multiload 250, summary of multicentre studies, 141
- Multiload Cu 250, removal due to bleeding and/or pain, 159
- Neem oil volatile fraction, spermicidal activity, 479
- Non-medicated vaginal ring, acceptability, 201
- Nonoxynol-9, effect as vaginal spermicide (monkey), 677
- Norethindrone, metabolism, 67

CONTRACEPTION

- Norethindrone acetate, metabolism, 67
- Norethindrone enanthate, metabolism, 67
- Norethisterone enanthate,
 - efficacy, side effects and acceptability, 179
 - metabolic effect, 13
- Norethisterone level, following use of ethynyloestradiol + norethisterone, 439
- Norethisterone POP, clinical experience, 489
- Norethynodrel, metabolism, 67
- Norgestimate, metabolism, 67
- Norplant^R, treatments for prolonged bleeding in users, 97
- Nova-T,
 - insertion immediately following induced abortion, 315
 - summary of multicentre studies, 141
- Oestradiol valerate + norethisterone oenanthate, efficacy, side effects and acceptability, 179
- Oral contraceptive,
 - ethinyl estradiol + cyproterone acetate, 225, 611
 - ethinylestradiol + desogestrel, 263, 275, 285, 423, 629
 - ethinylestradiol + gestodene, 263, 423
 - ethinylestradiol + levonorgestrel, 13, 497, 535, 597
 - ethinyl estradiol + lynestrenol, 497
 - ethinylestradiol + norethindrone, 253
 - ethinylestradiol + norethindrone acetate, 253
 - ethinyl estradiol + norethisterone, 497
 - ethinyl estradiol + norgestrel, 597
 - ethinylestradiol + dl-norgestrel, 253
 - ethinyl estradiol + L-norgestrel, 29
 - ethynodiol diacetate, 489
 - ethynyloestradiol + norethisterone, 439
 - levonorgestrel, 489
 - mestranol + norethisterone, 497
 - norethisterone, 489
- Oral contraceptive pill users, change in hypothalamic-pituitary-ovarian axis during placebo therapy week, 597
- Oral contraceptive use, relation to dietary habits and alcohol consumption, 171
- Oral contraceptives, views of alleged advantages and disadvantages, 507
- Organ weights, effect of styrene maleic anhydride (monkey), 337
- Ovarian function,
 - effect of ethinylestradiol + desogestrel, 285
 - effect of ethinylestradiol + 3-keto desogestrel, 285
 - effect of levonorgestrel-releasing IUD, 51
 - effect of Nova-T, 51
- Pelvic inflammatory disease (PID), following Nova-T insertion, 315
- PG (prostaglandin)
- pH in testis and epididymis, effect of vasectomy (rat), 589
- Pharmacodynamic and pharmacokinetic study, ethinyl-oestradiol + norethisterone, 439

- Pharmacokinetics,
 - ethinylestradiol + desogestrel, 629
 - ethinylestradiol + 3-keto-desogestrel released from vaginal rings, 629
- Phospholipid contents of sperm, effect of gossypol, 573
- PID (pelvic inflammatory disease)
- PID/salpingitis,
 - use of copper-releasing IUDs, 379
 - use of levonorgestrel-releasing IUD, 361
 - use of TCu 380Ag, 361
- Placebo therapy week of oral contraceptive pills, effect on gonadotropin and estradiol secretion, 597
- Polycystic ovary syndrome, use of ethinylestradiol + cyproterone acetate, 611
- Polyvinylalcohol films containing spermicides, use as vaginal contraceptive, 677
- Pregnancy,
 - changes in uterine surface epithelium (rat), 655
 - relation to surface topographic changes of IUCDs, 643
- POP (progestogen-only pill)
- Pregnancy rate,
 - copper-bearing IUDs, 141, 159
 - copper-releasing IUDs, 379
 - levonorgestrel-releasing IUD, 361
 - Lippes Loop D, 159
 - Mahua Ring, 391
 - TCu 380Ag, 361
- Pregnanediol-3 α -glucuronide level, effect of ethinyl estradiol + L-norgestrel, 29
- Problems, use of condoms, 523
- Progesterone level,
 - effect of ethinylestradiol + 3-keto desogestrel, 285, 563
 - effect of ethinyl estradiol + ST-1435, 111
 - effect of ethinylestradiol + norethisterone, 439
 - effect of 3-keto desogestrel, 1
 - effect of levonorgestrel, 51
 - effect of Nova-T, 51
 - effect of RU 486, 323
 - effect of tamoxifen, 323
- Progestogen-only pills, clinical experience, 489
- Progestogen-releasing delivery systems, effects on endometrium, endo- and exocervix, 403
- Progestogens, effect of local release on endometrium, endo- and exocervix, 403
- Pyrimethamine, effect on fertility (male rat), 667
- Radioimmunoassay, ST-1435, 555
- Release rates, ethinylestradiol + 3-keto-desogestrel vaginal rings, 629
- Removal rate,
 - copper-bearing IUDs, 159
 - Lippes Loop D, 159
 - Mahua Ring, 391
- Removals, use of copper-releasing IUDs, 379

CONTRACEPTION

- Reproductive system, effect of Anandron (male rat), 121
- RU 486 (mifepristone),
cervical priming prior to surgically induced abortion, 191
effect on non-pregnant uterine contractility, 323
- Seborrhea, effect of ethinylestradiol + cyproterone acetate, 611
- Serum chemistries, effect of ethinyl estradiol + ST-1435, 111
- SHBG (sex hormone binding globulin)
- SHBG capacity,
effect of ethinylestradiol + cyproterone acetate, 611
effect of ethinylestradiol + desogestrel, 285
effect of ethinylestradiol + 3-keto desogestrel, 285, 563
effect of ethynloestradiol + norethisterone, 439
effect of 3-keto desogestrel, 1
effect of levonorgestrel, 51
effect of Nova-T, 51
- Side effects,
use of condoms, 621
use of levonorgestrel-releasing IUD, 361
use of low-dose oral contraceptives, 253
use of progestogen-only pills, 489
use of TCu 380Ag, 361
- Socioeconomic factors, influence on contraceptive use, 507
- Sperm penetration test,
use of levonorgestrel-releasing IUD, 51
use of Nova-T, 51
- Spermatogenesis, effect of Anandron (rat), 121
- Spermatozoa maturation, effect of cyproterone acetate (monkey), 349
- Spermicidal activity, volatile fraction of neem oil, 479
- Spermicidal potency, alkyloxynol-741, nonoxynol-9 and chlorhexidine (monkey), 677
- ST-1435 (16-methylene-17 α -acetoxy-19-nor-4-pregnene-3,20-dione), radioimmunoassay, 555
- ST-1435 level,
following use of ethinyl estradiol + ST-1435 vaginal ring, 111
following use of ST-1435 subcutaneous capsule, 555
- ST-1435 subcutaneous capsule, milk and plasma concentrations of ST-1435, 555
- Sterilization, use of tetracycline or ampicillin following procedure, 297
- Striga lutea plant, antifertility efficacy (rat), 467
- Styrene maleic anhydride,
chronic toxicity study (monkey), 337
male mediated teratogenic potential evaluation (rabbit), 215
- Sulphanilamide, effect on fertility (male rat), 667

- Sulphapyridine,
 - effect on fertility (male rat), 667
 - effect on folate metabolism (rat), 667
- Sulphonamides,
 - effect on fertility (male rat), 667
 - effect on folate metabolism (rat), 667
- Tamoxifen, effect on non-pregnant uterine contractility, 323
- TCu 200, removal due to bleeding and/or pain, 159
- TCU 220, removal due to bleeding and/or pain, 159
- TCu220C, summary of multicentre studies, 141
- TCu 380A,
 - removal due to bleeding and/or pain, 159
 - summary of multicentre studies, 141
- TCu 380Ag, clinical trial, 361
- Teratogenic potential evaluation, styrene maleic anhydride (rabbit), 215
- Termination of pregnancy,
 - use of gemeprost vaginal pessaries, 43
 - use of RU 486 for cervical priming prior to surgically induced abortion, 191
- Termination rate,
 - levonorgestrel-releasing IUD, 361
 - TCu 380Ag, 361
- Testis,
 - effect of Anandron (rat), 121
 - effect of vasectomy on in situ pH (rat), 589
- Testosterone level,
 - effect of 3 Ad (monkey), 235
 - effect of 20 Aet-2 (monkey), 235
 - effect of Antide (monkey), 209
 - effect of cyproterone acetate (monkey), 349
- Tetracycline, use following minilaparotomy sterilization, 297
- Trimethoprim, effect on fertility (male rat), 667
- Triphasic ethinylestradiol + levonorgestrel,
 - changes in hypothalamic-pituitary-ovarian axis during placebo therapy week, 597
 - effect on dysmenorrhea, 497
 - effect on lipid and lipoprotein metabolism, 535
 - metabolic effect, 13
- Triphasic ethinylestradiol + norethindrone, effect on bleeding pattern, 253
- Triphasic ethinyl estradiol + norethisterone, effect on dysmenorrhea, 497
- Triphasic ethinylestradiol + dl-norgestrel, effect on bleeding pattern, 253
- Tubal ligation, use of Falope ring or clip, 309
- Use patterns of contraceptive methods, condom user responses, 523
- Uterine bleeding, relation to surface topographic changes of IUCDs, 643
- Uterine cavity measurement, prior to insertion of Mahua Ring, 391

CONTRACEPTION

- Uterine contractility,
 - effect of RU 486 with $\text{PGF}_{2\alpha}$, 323
 - effect of tamoxifen with $\text{PGF}_{2\alpha}$, 323
- Uterine pain and side effects, use of gemeprost vaginal pessaries, 43
- Uterine surface epithelium, changes during pregnancy (rat), 655
- Vaginal contraceptive, acceptability of non-medicated vaginal ring, 201
- Vaginal cultures, use of non-medicated vaginal ring, 201
- Vaginal irritation test, volatile fraction of neem oil (rabbit), 479
- Vaginal release of progestogens, effect on endometrium, 403
- Vaginal ring,
 - containing no steroid, 201
 - releasing ethinylestradiol + 3-keto desogestrel, 285, 563, 629
 - releasing ethinyl estradiol + ST-1435, 111
- Vas deferens, effect of styrene maleic anhydride (monkey), 337
- Vasectomy, effect on pH in testis and epididymis (rat), 589

